Can HIV-1 superinfection compromise antiretroviral therapy?
Chakraborty, Bikrama; Kiser, Pattia; Rangel, Hector Ra; Weber, Jana; Mirza, Muneera; Marotta, Michael La; Asaad, Robertb; Rodriguez, Benignob; Valdez, Hernanb; Lederman, Michael Mb; Quiñones-Mateu, Miguel Ea,b
aDepartment of Virology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; and bCenter for AIDS Research, Case Western Reserve University/University Hospitals, Cleveland, OH, USA.
Sponsorship: Research performed at the Cleveland Clinic Foundation (M.E.Q-M.) was supported by research grants from the National Heart, Lung, and Blood Institute, National Institutes of Health (5-KO1-HL67610-03), and the Center for AIDS Research (AI36219) at Case Western Reserve University. Nucleotide sequences described in this study have been submitted to GenBank under the following accession numbers: C2V3 gp120-coding region (AY427722 to AY427743) and reverse transcriptase (AY427744 to AY427751).
Received: 24 July 2003; revised: 6 August 2003; accepted: 8 September 2003.
Antiretroviral therapy has been able to restore health to HIV-infected patients, and this success may have played a role in the increasing rates of unsafe sex among HIV-infected individuals . In addition, recent studies have shown that chronically HIV-infected individuals may be superinfected with a second HIV-1 strain [2–5]. We used a small cohort of patients to test whether the occurrence of antiretroviral therapy failure might be related in some instances to superinfection with HIV-1 drug-resistant variants.
To detect potential HIV-1 superinfection events, we analysed samples from the specimen repository at the Center for AIDS Research, Case Western Reserve University, Cleveland, Ohio, USA. Plasma samples from HIV-infected individuals who suddenly experienced virological failure were identified. Patients who were receiving antiretroviral therapy, who had non-progressive HIV-1 infection with low to undetectable plasma viremia (<400 copies/ml), and who unexpectedly experienced virological failure (more than one log increase in the plasma viral load in less than a month) despite recorded good adherence to treatment were selected. Ninety-four patients were originally identified, and two samples were analysed, one obtained before and one after virological failure, from six patients with the highest increase in viral load. Two additional clinical cases were included, which had a suspicion of HIV-1 superinfection after having unprotected sex with HIV-infected individuals. Plasma viral RNA was reverse transcribed and the protease-coding region, the reverse transcriptase (RT) polymerase domain, and the C2V3 gp120-coding region were polymerase chain reaction amplified and sequenced . Intra and interpatient nucleotide sequence diversities were calculated and neighbor joining trees were constructed to compare the phylogenetic relationships of pol and env global sequences .
HIV-1 sequences from seven patients formed monophyletic clusters in each genomic region analysed. The median nucleotide distance between intrapatient pol and env sequences was 1.5 and 4.1%, respectively. For patient 3, however, the pol and env longitudinal sequences did not cluster together in the phylogenetic trees, and consequently higher nucleotide distances were obtained (i.e. 5% in pol and 15% in env) (Fig. 1a). This highly antiretroviral-experienced patient showed a sudden increase in viral load (from 12 532 to 662 889 copies/ml) in the short period between samples 3A and 3B (9 November 1998 and 7 December 1998, respectively) (Fig. 1b).
To investigate this ‘multiple infection’ by phylogenetically unlinked viruses further, six extra plasma samples were analysed. All longitudinal sequences in both genomic regions clustered together, with the exception of sample 3B (Fig. 1c). Exhaustive quality control experiments ruled out potential cross-contamination with other sequences in our laboratory (data not shown). Although sequences before and after the rapid increase in viral load showed a profile of drug-resistance mutations compatible with the antiretroviral history of the patient, sequence 3B was wild type in both protease and RT and showed significant amino acid diversity in the env gene (Fig. 1d). A detailed analysis of his clinical history revealed that patient 3 was not adherent to antiretroviral therapy during the period between the collection of samples 3A and 3B, which could explain the rapid increase in viral load (Fig. 1b). Was this the result of transient superinfection with a wild-type (more fit) HIV-1 isolate during treatment interruption or the selection of a pre-existent virus established during an original HIV-1 co-infection? Previous studies have described HIV-1 superinfections with different wild-type viruses [2,3], or by wild-type HIV-1 strains re-infecting patients harboring drug-resistant viruses after a short period of treatment interruption [4,5]. The latter could have been the case for patient 3, but without the source of the second genetically distinct HIV-1 strain, it is difficult to distinguish between consecutive or simultaneous infection.
There is still the possibility, although not described to date, that patients infected with wild-type HIV-1 isolates and under successful antiretroviral therapy may be exposed to drug-resistant viruses. These mutant strains would have a significant selective advantage in this new environment, which could lead them to outcompete the original wild-type HIV-1 strain and cause antiretroviral therapy failure. We have recently demonstrated that, in vitro, the superinfecting HIV-1 strain must have a phenotypic advantage (increased fitness) over the original virus, which favors superinfection (unpublished results). However, the probability that an individual infected with wild-type HIV-1 and receiving antiretroviral therapy will be exposed to drug-resistant HIV-1 strains may be low. A recent study  was not able to detect HIV-1 superinfection after analysing protease and RT sequences from more than 700 patients. Conversely, high rates of transmission and prevalence of HIV-1 drug resistance mutations in antiretroviral-naive patients have been reported , which implies that the theoretical risk of re-infection with mutant HIV-1 strains exists. Therefore, HIV-seroconcordant partners should be informed of the theoretical risk of superinfection, especially when only one partner is receiving antiretroviral therapy.
1. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS
2. Ramos A, Hu DJ, Nguyen L, Phan KO, Vanichseni S, Promadej N, et al
. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol
3. Jost S, Bernard MC, Kaiser L, Yerly S, Hirschel B, Samri A, et al
. A patient with HIV-1 superinfection. N Engl J Med
4. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, et al
. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature
5. Koelsch KK, Smith DM, Little SJ, Ignacio CC, Macaranas TR, Brown AJ, et al
. Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS
6. Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, Fransen K, et al
. Role of baseline pol genotype in HIV-1 fitness evolution. J Acquired Immune Defic Syndr
7. International AIDS Society – USA. Topics in HIV medicine, drug resistance mutations in HIV-1
. Available at: http://www.iasusa.org
. Accessed 19 August 2003.
8. Gonzales M, Delwart E, Rhee S-Y, Tsui R, Zolopa AR, Taylor J, Shafer RW. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis
9. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al
. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med
© 2004 Lippincott Williams & Wilkins, Inc.